Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
Community-acquired Bacterial Pneumonia (CABP) Treatment Drugs Market
Community-acquired bacterial
pneumonia (CABP) is a type of pneumonia that is contracted outside of a
hospital or healthcare setting. The treatment for CABP involves antibiotics,
which are medications that kill the bacteria causing the infection. The global
market for drugs used to treat CABP is expected to grow in the coming years due
to the increasing prevalence of pneumonia and the development of new
antibiotics.
The Community-acquired
Bacterial Pneumonia (CABP) Treatment Drugs Market is highly
competitive, with several pharmaceutical companies vying for a share of the
market. Some of the key players in this market include Pfizer Inc., Merck &
Co. Inc., Roche Holdings AG, GlaxoSmithKline Plc, and AstraZeneca Plc.
Factors such as increasing
awareness about pneumonia, the rising geriatric population, and the development
of new antibiotics are expected to drive the growth of the Community-acquired
Bacterial Pneumonia (CABP) Treatment Drugs Market in the
coming years. However, the emergence of antibiotic-resistant strains of
bacteria and the high cost of new antibiotics may pose a challenge to the
growth of this market.
The high incidence of community-acquired pneumonia is anticipated
to increase demand for medications that treat CABP, which will fuel market
expansion throughout the forecast period. For instance, an article from the
Asian Pacific Association of Respirology from 2017 states that in Central
Vietnam, the incidence of all-cause CAP was predicted to be 0.81 per 1,000
people each year, increasing to 6.95 per 1,000 people each year among those who
were 75 or older.
Moreover, the impact of HIV was a major factor in the rising
prevalence of CAP. For instance, according to the Asian Pacific Association of
Respirology, a 2017 paper claims that in 2017, HIV was the primary cause of CAP
if untreated, which was linked to a 17- to 35-fold rise in pneumococcal
pneumonia in the Sub-Saharan Africa area.
Comments
Post a Comment